Next, we assessed DCX- and LIS1-KD expression profiles in the context of primary NB using three clinically relevant dichotomies (stage 4S versus stage 4, stages 1|2 versus stage 4; MYCN-nonamplified versus MNA tumors). This evidence concerns the gene DCX and neuroblastoma.